Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — Vogenx, Inc.

Accession: 0001185185-26-005214

Filed: 2026-11-06

Period: 2026-11-06

CIK: 0001903784

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — vogenx8k110426.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (vogenxex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: vogenx8k110426.htm · Sequence: 1

false

0001903784

0001903784

2026-11-06

2026-11-06

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d)

of

the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): November 6, 2026

VOGENX, INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-43441

86-3697324

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

PO

Box 19469

Raleigh,

North Carolina

27619

(Address of principal executive offices)

(Zip Code)

(919) 659-5677

(Registrant’s

telephone number, including area code)

Not

Applicable

(Former name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common Stock, $0.0001 par value per share

VOGX

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company ☒

If

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.

Results of Operations and Financial Condition.

On November 6, 2026, Vogenx, Inc. issued a

press release announcing its financial results for the fiscal quarter ended September 30, 2026. A copy of the press release is

attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Current Report on Form 8-K, including

Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it

be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall

be expressly set forth by specific reference in such a filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

99.1

Press release, dated November 6, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Vogenx, Inc.

Date: November 6, 2026

By:

/s/ James Green

Name:

James Green

Title:

Chief Executive Officer

2

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: vogenxex99-1.htm · Sequence: 2

Exhibit 99.1

Vogenx Reports Third Quarter 2026 Financial

Results and Business Highlights

Advances PBH Development Program Following August

2026 Initial Public Offering

Strengthens Balance Sheet with $82.1 Million

in Total Cash, Cash Equivalents, and Marketable Securities

RALEIGH, NC / ACCESS Newswire / November 6, 2026 – Vogenx,

Inc. (Nasdaq: VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases,

today announced its financial results for the third quarter and provided a corporate update.

“Our third quarter performance marks a pivotal milestone for

Vogenx following our successful public listing in August," said James Green, Chief Executive Officer of Vogenx. “The EMERGE

study is now up and running and we have added critical headcount across the Company, positioning us to advance the development of mizagliflozin

for both post-bariatric hypoglycemia (PBH) and gastroparesis.”

Recent Corporate & Clinical Highlights

Clinical Pipeline Update:

In October 2026, the Company initiated

EMERGE (NCT07760961), a randomized, placebo-controlled, double-blind, parallel-group, Phase 2b study evaluating mizagliflozin 5 mg and

10 mg for 28 days in approximately 36 adults with PBH. The EMERGE study will be conducted at multiple centers in the United States, with

topline results expected in the second half of 2027. The Company plans to initiate a Phase 2 study of mizagliflozin for gastroparesis

in the first half of 2027.

Initial Public Offering:

In August 2026, the Company completed

its $93.4 million IPO, pursuant to which the Company issued and sold 7,187,500 shares of its common stock at a public offering price of

$13.00 per share, including 937,500 additional shares of its common stock pursuant to the exercise in full by the underwriter of its option

to purchase shares of common stock from the Company at the IPO price. After deducting underwriting discounts, commissions and offering

expenses payable by the Company, the Company received net proceeds from the IPO of approximately $84.4 million.

Leadership and Board Updates:

In September 2026, Ken Toombs was appointed

as an independent member of the Vogenx board of directors and chair of the audit committee. In October 2026, Rich Gorman joined the Vogenx

management team as Chief Commercial Officer concurrently with his resignation as an independent member of the board of directors, effective

October 12, 2026. Mr. Gorman will lead commercial operations, corporate strategy and business development.

Financial Highlights

● Cash Position: As of September 30, 2026, the Company’s cash, cash equivalents, and marketable securities totaled $82.1

million, compared to $601 thousand as of December 31, 2025. This significant increase was secured through net proceeds from the Company’s

August 2026 IPO.

● Research and Development (R&D) Expenses: R&D expenses for the three months ended September 30, 2026, rose to $1.1 million,

compared to $125 thousand for the same period in 2025. The increase was primarily driven by $714 thousand in direct program expenses for

the PBH EMERGE Phase 2b study and expanded department headcount.

● General and Administrative (G&A) Expenses: G&A expenses for the three months ended September 30, 2026, were $704 thousand,

compared to $178 thousand for the three months ended September 30, 2025. The increase reflects $237 thousand in personnel costs and $214

thousand in incremental public company operational expenses.

● Net Loss and EPS: Net loss for the three months ended September 30, 2026, was $4.9 million, or $(0.47) per basic and diluted

share, compared to a net loss of $284 thousand, or $(0.05) per basic and diluted share, for the same period in 2025. The

net loss for the quarter was the result of operating expenses of $1.8 million, the change in warrant liability of $3.4 million offset by

interest income of $0.3 million.

——————————————————————————————

About Vogenx, Inc.

Vogenx, Inc. (Nasdaq: VOGX) is a clinical-stage biopharmaceutical company

based in Raleigh, North Carolina, focused on the discovery and development of novel therapeutics for the treatment of serious metabolic

and gastrointestinal diseases with high unmet medical need. The Company is developing its lead product candidate, mizagliflozin, for post-bariatric

hypoglycemia, gastroparesis and GIP-dependent Cushing's Syndrome. For more information, please visit https://vogenx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995, including statements regarding the design, conduct, enrollment, timing and results

of the EMERGE Phase 2b study, including the expected timing of topline data; the potential of mizagliflozin to treat post-bariatric hypoglycemia

and other indications; anticipated clinical development plans and timelines; the anticipated use of proceeds from the Company's initial

public offering, and its capital requirements and need for additional financing; and the potential market opportunity for its product

candidates. Words such as "anticipate," "believe," "continue," "estimate," "expect,"

"intend," "may," "plan," "potential," "should," "will" and similar expressions

are intended to identify forward-looking statements. These statements are based on management's current expectations and are subject to

risks and uncertainties that could cause actual results to differ materially, including risks related to the initiation, timing, enrollment

and results of clinical trials, the possibility that results of earlier studies may not be predictive of later studies, regulatory review,

competition, including the possibility that competitors obtain regulatory approval before the Company, reliance on third parties including

clinical research organizations and clinical trial sites, the Company's license from Kissei Pharmaceutical Co., Ltd., the Company's need

for additional capital, its limited operating history, its dependence on a small number of key personnel, and the material weaknesses

identified in its internal control over financial reporting. Additional information on these and other risks is contained in the Company's

filings with the Securities and Exchange Commission (SEC), including the Company’s Quarterly Report on Form 10-Q for quarter ended

June 30, 2026 filed with the SEC on September 17, 2026. Forward-looking statements speak only as of the date of this release, and Vogenx

undertakes no obligation to update them except as required by law.

2

Vogenx, Inc.

Condensed Balance Sheets

Unaudited

September 30,

2026

December 31,

2025

Assets

Current assets

Cash and cash equivalents

$ 5,126,137

$ 601,010

Deferred offering costs

-

63,363

Marketable securities

76,991,943

-

Prepaid expenses and other current assets

725,193

16,797

Total current assets

82,843,273

681,170

Total assets

$ 82,843,273

$ 681,170

Liabilities and stockholders’ equity (deficit)

Current liabilities

Accounts payable

$ 523,570

$ 62,964

Accrued expenses

318,900

709,818

Warrant liability

-

11,323

Convertible promissory notes payable, related party

-

816,300

Total current liabilities

842,470

1,600,405

Total liabilities

842,470

1,600,405

Total stockholders’ equity (deficit)

82,000,803

(919,235 )

Total liabilities and stockholders’ equity (deficit)

$ 82,843,273

$ 681,170

3

Vogenx, Inc.

Condensed Statements of Operations

(Unaudited)

Three Months Ended

September 30,

Nine Months Ended

September 30,

2026

2025

2026

2025

Operating expenses

Research and development

$ 1,079,000

$ 124,813

$ 1,473,697

$ 430,517

General and administrative

703,736

177,664

1,127,576

554,818

Total operating expenses

1,782,736

302,477

2,601,273

985,335

Other (expense) income

Change in fair value of warrant liability

(3,436,669 )

16,984

(3,426,761 )

43,876

Change in fair value of convertible promissory notes payable, related party

(26,777 )

-

(78,177 )

-

Interest income

338,579

1,086

338,726

5,636

Total other (expense) income

(3,124,867 )

18,070

(3,166,212 )

49,512

Net loss

$ (4,907,603 )

$ (284,407 )

$ (5,767,485 )

$ (935,823 )

Net loss per common share – basic and diluted

$ (0.47 )

$ (0.05 )

$ (0.82 )

$ (0.17 )

Weighted average common shares outstanding – basic and diluted

10,404,831

5,451,873

6,995,883

5,451,873

Contact

Harrison Seidner, PhD and Nilesh Talele, PhD

WaterSeid Partners, Inc.

ir@vogenx.com

4

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.3

Cover

Nov. 06, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Nov. 06, 2026

Entity File Number

001-43441

Entity Registrant Name

VOGENX, INC.

Entity Central Index Key

0001903784

Entity Tax Identification Number

86-3697324

Entity Incorporation, State or Country Code

DE

Entity Address, Address Line One

PO

Box 19469

Entity Address, City or Town

Raleigh

Entity Address, State or Province

NC

Entity Address, Postal Zip Code

27619

City Area Code

919

Local Phone Number

659-5677

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.0001 par value per share

Trading Symbol

VOGX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration